Authorised medicine
Forzinity
- Specified elamipretide formulation
- Named manufacturer and quality controls
- Defined patient group and indication
- Prescribing information and adverse-event system
- Confirmatory evidence obligation
Evidence profile · O-003
SS-31 / elamipretide: medicine evidence versus a research vial
A narrow US approval changed the status, not the scope. Forzinity is authorised for a defined Barth syndrome population; that does not establish longevity, general mitochondrial support or an online SS-31 vial.
Elamipretide is no longer investigational everywhere. In September 2025, the US FDA granted accelerated approval to Forzinity to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. The decision is narrow, requires confirmatory work and does not validate anti-ageing claims or research-channel SS-31 products.
The authorised medicine and a vial marketed as SS-31 are not interchangeable. Approval attaches to a defined formulation, manufacturer, indication, label and pharmacovigilance system. A separate product still needs evidence of identity, amount, impurities, sterility, endotoxin and clinical equivalence. No UK marketing authorisation was identified for elamipretide.
Status correction
What changed in September 2025
The FDA approved Forzinity under its accelerated approval pathway for patients with Barth syndrome who meet the labelled weight threshold. The approved purpose is to improve muscle strength. Continued approval may depend on a confirmatory randomised, double-blind, placebo-controlled trial.
This is genuine regulatory evidence. It is not a general endorsement of elamipretide for fatigue, healthy ageing, athletic recovery or unspecified mitochondrial dysfunction. It also does not create a UK authorisation.
Product distinction
Forzinity and a research vial are different evidence objects
Research channel
Product labelled SS-31
- Name alone does not prove identity
- Stated amount needs batch-specific testing
- Impurity and aggregation profile may differ
- Sterility and endotoxin need separate evidence
- No automatic clinical equivalence
Evidence scope
What the authorisation can and cannot support
| Proposition | Evidence position | Boundary |
|---|---|---|
| Muscle strength in labelled Barth syndrome patients | Supported for the authorised US medicine under accelerated approval | Confirmatory evidence is required |
| General mitochondrial disease treatment | Not established by the label | Each disease and outcome needs direct evidence |
| Longevity or anti-ageing | Not established | Mechanism and disease evidence do not prove longer or healthier life |
| Online SS-31 vial equivalence | Not established | Product identity, manufacture and clinical comparability are unverified |
Regulatory reading
Accelerated approval carries an evidence condition
The FDA relied on an intermediate endpoint and required a confirmatory trial to verify and describe clinical benefit. That condition belongs in the same sentence as the approval claim because it changes how readers should interpret certainty.
The label also defines formulation, route, warnings and the intended population. None of those controls can be inferred from a marketplace photograph or a certificate that reports only chromatographic purity.
The development record also shows why status updates matter. Earlier FDA reviews questioned whether the submitted programme contained adequate and well-controlled evidence for effectiveness. The later accelerated approval is the current regulatory fact, but it does not erase the remaining uncertainty. A sound profile records both the decision and the evidence obligation that came with it.
DecisionAccelerated approval
EndpointMuscle strength
PopulationBarth syndrome, weight threshold
ConditionConfirmatory trial required
Decision boundary
What remains unknown
Evidence outside Barth syndrome should start again with the exact disease, patient group and outcome. A mitochondrial mechanism is too broad to transfer an effect between rare genetic disease, primary mitochondrial myopathy, age-related fatigue and healthy longevity. Each claim needs its own trial programme, and each programme must use a defined product rather than a marketplace category. Negative, neutral and positive findings all need full reporting so the evidence record does not become a selection of favourable signals.
- The confirmatory magnitude and durability of clinical benefit in Barth syndrome.
- Whether elamipretide benefits other mitochondrial diseases or patient-important outcomes.
- Whether it changes healthy ageing, lifespan or general fatigue.
- Whether any research-channel vial contains elamipretide at the stated amount.
- Whether that vial meets suitable impurity, sterility, endotoxin and stability controls.
- Whether future UK or European regulatory decisions will match the narrow US decision.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| FDA: Forzinity approval letter | The 19 September 2025 accelerated approval, narrow indication and required confirmatory trial. | It does not authorise longevity use, other products or use in the UK. | |
| FDA: Forzinity prescribing information | The defined formulation, population, indication and current safety information. | A US label does not verify a research-channel vial. | |
| FDA: Drug Trials Snapshot for Forzinity | FDA’s public account of the evidence used for the approval. | A snapshot does not extend the indication beyond the label. | |
| MHRA products database | The official route to check current UK marketing authorisations. | It does not authenticate a product sold under the SS-31 name. |
Continue the investigation
Read the connected evidence
- what US approval means hereSeparate a narrow foreign authorisation from UK status and marketplace claims.
- SS-31 and mitochondrial claimsSee why disease-specific evidence does not establish longevity.
- what tests can proveReview the methods needed for identity, amount and microbiological attributes.
- how we assess human evidenceRead how regulatory scope and confirmatory conditions affect the verdict.
Quick answers
Frequently asked questions
Is SS-31 FDA approved?
Elamipretide is FDA approved as Forzinity for a narrow Barth syndrome indication in patients who meet the labelled weight threshold. That does not approve every SS-31 product or use.
What does accelerated approval mean?
The FDA may approve on an intermediate endpoint reasonably likely to predict benefit, with confirmatory work required to verify and describe that benefit.
Does Forzinity prove anti-ageing benefits?
No. The decision concerns muscle strength in a defined rare disease population, not longevity or healthy ageing.
Is elamipretide authorised in the UK?
No UK marketing authorisation was identified. Check the current MHRA products database for the exact product and presentation.
Is a research SS-31 vial equivalent to Forzinity?
Not on the basis of a shared molecule name. Identity, formulation, manufacture, quality controls and clinical comparability would all need evidence.
What remains unknown?
Confirmatory clinical benefit, effects in other conditions and the identity and quality of research-channel products remain unresolved.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-003, SS-31 and elamipretide: approval, trials and vial claims was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.